BUSINESSDESK: Genesis Research and Development, the unprofitable developer of gene silencing technology, has placed 9.1 million shares, equivalent to 20% of its existing capital, to Delight Grace, a British Virgin Islands-registered firm.
The shares were sold at 1 cent apiece, less than half the 2.5 cents they last traded at on June 29, raising $91,000.
In notes for discussion at the annual meeting last month, the company said there were “very tight market conditions for funding biotech” and a low share price meant any placement “will only raise a small amount”.
In March, the company told NZX Market Supervision that it was “able to pay its debts as they fall due and continues to be solvent”.
The statement was in response to a query from the regulator which said a shareholder had complained the company was not solvent.
UBNZ Asset Holdings, which was associated with the failed bid for the Crafar Farms, emerged last year with a 16% holding in Genesis.
The research firm is trying to negotiate a "reverse takeover" of Mariposa Health, an unlisted Australia medical researcher.
Genesis shares traded as high as $7.55 in 2001.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- European milk output falls for first time in more than a year, Fonterra says
- Warminger stood to gain significant bonus, court hears
- Sky will take a gamble and put Westworld, aka 'the next Game of Thrones' on Neon
- Where polls stand on the eve of the first US presidential debate
- Spark says 130,000 Xtra mail address at risk after Yahoo hack
Most listened to
- FMA counsel Justin Smith QC described Mr Warminger’s background and the pressure he was under to perform
- Media Snapchat: NBR’s Nick Grant ponders the Human Rights Commission’s role in RHOAKL racism row
- ASB's Jane Turner discusses what's behind NZ's widest month trade deficit
- Kathmandu's Xavier Simonet and Reuben Casey talk through the retailer's results.
- BNZ's Kymberly Martin and Massey University's David Tripe on mortgage rates.